08:36 AM EDT, 06/11/2024 (MT Newswires) -- A Food and Drug Administration advisory panel voted unanimously late Monday to recommend approval of Eli Lilly's ( LLY ) Alzheimer's drug donanemab, according to a video transcript of the meeting.

The 11 committee members agreed that available data showed donanemab's effectiveness in treating early-stage Alzheimer's patients and that the drug's benefits outweighed the risks.

The US health agency is not obligated to follow the recommendations of its advisory panels but often does so.

Lilly shares were more than 2% higher in premarket trading.

Price: 882.40, Change: +17.40, Percent Change: +2.01